儿童特应性皮炎的治疗进展  

Progress in treatment of childhood atopic dermatitis

作　　者：朱晓娜(综述) 夏宇(审校)[1] Zhu Xiaona;Xia Yu(Department of Rheumatology and Immunology,Shenzhen Children′s Hospital,Shenzhen 518000,China)

机构地区：[1]深圳市儿童医院风湿免疫科,518000

出　　处：《国际儿科学杂志》2021年第5期327-330,共4页International Journal of Pediatrics

基　　金：深圳市三名工程项目(SZSM201812002);广东省高水平临床重点专科(深圳市配套建设经费)资助(SZGSP012)。

摘　　要：特应性皮炎是复杂的慢性复发性炎症性皮肤病,儿童症状较成人轻,但其发病率高且易反复发作,可严重影响患儿及家属的身心健康。既往对特应性皮炎的治疗多局限于糖皮质激素及免疫抑制剂,长期使用药物不良反应明显,故不适于儿童。随着对发病机制的深入了解,越来越多侧重于靶向特定细胞因子或其受体以干预炎症通路的新的治疗方法被发现及应用,该文对特应性皮炎的治疗进展进行综述,旨在为优化儿童特应性皮炎的治疗提供帮助。Atopic dermatitis is a complex chronic,relapsing inflammatory skin disease.Atopic dermatitis in children is usually less severe than in adults,but it is with a high incidence and is susceptible to relapse.Therefore,the physical and mental health of children and their family maybe seriously affected.In the past,the treatments of atopic dermatitis have been limited to glucocorticoids and immunosuppressants.It is unsafe for children because of their toxicities.With the in-depth understanding of pathogenesis,more and more new therapies that focus on intervening in the inflammatory pathway by targeting specific cytokines or their receptors have been found and applied.This article reviews the progress of treatment of the disease to provide new insights for the optimal treatment of atopic dermatitis.

关 键 词：特应性皮炎 儿童 治疗 生物制剂 小分子靶向药 

分 类 号：R72[医药卫生—儿科]